Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0U2XU
|
||||
| Former ID |
DNCL002657
|
||||
| Drug Name |
XEN-2174
|
||||
| Indication | Cancer pain [ICD9: 140-229, 338,780; ICD10:R52, G89] | Phase 2 | [1] | ||
| Company |
Xenome
|
||||
| Target and Pathway | |||||
| Target(s) | Sodium-dependent noradrenaline transporter | Target Info | Inhibitor | [2] | |
| PANTHER Pathway | Adrenaline and noradrenaline biosynthesis | ||||
| Reactome | Na+/Cl- dependent neurotransmitter transporters | ||||
| WikiPathways | Monoamine Transport | ||||
| NRF2 pathway | |||||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021315) | ||||
| REF 2 | Spinal noradrenaline transporter inhibition by reboxetine and Xen2174 reduces tactile hypersensitivity after surgery in rats. Pain. 2005 Feb;113(3):271-6. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.